BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Viveve-Sponsored Research to be Published in Journal of Sexual Medicine


8/13/2010 8:15:18 AM

PALO ALTO, Calif., Aug. 12 /PRNewswire/ -- Viveve, Inc., a women's sexual health company that has developed a non-surgical procedure to treat vaginal laxity resulting from childbirth, recently sponsored a clinical trial whose results will be published in the September 2010 issue of the Journal of Sexual Medicine. A promising step, this pilot study demonstrates the safety and efficacy of Viveve's radiofrequency (RF) treatment, with self-reported questionnaire responses indicating post-procedure improvement in both sexual satisfaction and vaginal tightness.

"Many women who give birth through vaginal delivery notice changes in their sexual satisfaction during intercourse," said Dr. Leah Millheiser, the lead author on the article and practicing Obstetrician and Gynecologist at Stanford Hospital in Palo Alto, California. "This research may contribute to our understanding of the impact of improved vaginal laxity on an increase in sexual function."

The peer-reviewed article, "Radiofrequency Treatment of Vaginal Laxity After Vaginal Delivery: Non-Surgical Vaginal Tightening," reports on findings from an IRB-approved pilot study that was the first to explore the use of the Viveve System, a non-surgical medical device to treat vaginal laxity post childbirth. The study included 24 women ages 25-44, who were treated using reverse gradient, volumetric RF energy delivered to the vaginal sub-mucosal tissue while protecting the surface with a coolant. All study participants had delivered at least one child vaginally. The procedure was well-tolerated with no topical anesthetics required and no adverse events reported.

"We are delighted with the pivotal results of this study and we feel very gratified the article has been accepted for publication," says Kerry Pope, CEO of Viveve. "We look forward to supporting future ground-breaking research as we continue our efforts to improve women's sexual health."

In addition to Dr. Millheiser, Rachel Pauls, M.D., Seth Herbst, M.D., and Bertha Chen, M.D., were authors on this article.

The published article can be viewed at www.viveve.com

About Viveve

Viveve is a privately held women's sexual health company based in Palo Alto, California. The Viveve System is a medical device used for the nonsurgical procedure of post-birth laxity of the vaginal introitus, a medically recognized quality of life condition.

The company's Series A financing was led by GBS Venture Partners and 5AM Ventures. For more information, visit the Viveve Web site at www.viveve.com or phone 650-321-3332.

SOURCE Viveve



Read at BioSpace.com

Viveve
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES